Tyruko®
ACTIVE PRINCIPLE:
natalizumab
INDICATION:
Multiple sclerosis
DATE:
22/09/2023
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
natalizumab
INDICATION:
Multiple sclerosis
DATE:
22/09/2023
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.